Replies to post #247385 on Innovation Pharmaceuticals Inc (IPIX)

[frrol]

Yes not a good comparison. Galectin's drug trial was dependent on biomarker endpoints, which are not as conclusive as clinical outcomes themselves, just predictive. The bar is higher for that, and understandably so.

I read somewhere that BTD applications have a 'granted' rate of about 30% to date. So we'll see.